Acquisition lets Alcon better meet rising demand

Article Excerpt

Alcon taps into long-term key trends—an aging population and greater wealth globally. In addition, technological changes make it hard for new entrants to gain significant market share. This all bodes well for its share price and investor returns. ALCON, $91.42, is a #1 Power Buy for 2025. The firm (New York symbol ALC; TSINetwork Rating: Average)(www.alcon.com; Shares outstanding: 499.7 million; Market cap: $46.1 billion; Dividend yield 0.4%) has agreed to acquire Lensar Inc. (symbol LNSR on Nasdaq). That firm is a global medical technology company focused on advanced laser solutions for the treatment of cataracts eye disease. Alcon will purchase all outstanding shares of Lensar for approximately $356 million, with a possible additional spend of $2.75 per share in cash. That will depend on Lensar achieving 614,000 cumulative procedures between January 1, 2026, and December 31, 2027. Currently, there are more than 5 million cataract procedures in the U.S., and approximately 32 million globally. Alcon is a #1 Power Buy for 2025. 2025…